Prevention and treatment of ocular inflammation with a new class of non-steroidal anti-inflammatory agents

J Ocul Pharmacol. Spring 1994;10(1):335-47. doi: 10.1089/jop.1994.10.335.

Abstract

New non-steroidal anti-inflammatory agents (NSAIAs) were tested on lens protein-, endotoxin- and interleukin-1-induced ocular inflammation. It was found that most NSAIAs, including REV 5901, mefenamic acid, indomethacin, CK-17 and CK-102, inhibited lens protein-induced inflammation. Endotoxin induced inflammation indirectly through the release of IL-1 which was inhibited by fewer agents, including CK-17, CK-102 and prednisolone. However, the direct effect of IL-1 can only be suppressed by CK-17 and prednisolone. Therefore, CK-17 could become an important NSAIA which acts similarly to corticosteroids yet produces no steroidal side effects. CK-17 was different from most NSAIAs as it affected little, if any, arachidonate metabolism. Most importantly, CK-17 was found to be 2-fold more potent than prednisolone in inhibiting IL-1-induced uveitis, while no side effects were noted at doses tested to date.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anterior Eye Segment / metabolism
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Chemotaxis, Leukocyte*
  • Crystallins
  • Female
  • Leukocytes
  • Leukotrienes / biosynthesis
  • Male
  • Prednisolone / therapeutic use
  • Prostaglandins / biosynthesis
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Retina / metabolism
  • Uveitis / chemically induced
  • Uveitis / drug therapy*
  • Uveitis / prevention & control*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Crystallins
  • Leukotrienes
  • Prostaglandins
  • Prednisolone